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Available online 15 July 2016Background: Live vaccines against measles (MV), tuberculosis (BCG), polio (OPV) and smallpox reducemortality
more than explained by target-disease prevention. The beneﬁcial nonspeciﬁc effects (NSEs) of MV are strongest
whenMV is given in presence of maternal antibodies. We therefore hypothesised that revaccination in presence
of prior immunity enhances beneﬁcial NSEs.
Methods: Literature search for studies of revaccination and mortality.
Findings: In two randomised trials (RCTs), two doses versus one dose of MV reduced all-cause mortality by 63%
(95% CI: 23–83%) from9 to 18months of age. In a quasi-experimental study two doses before and after 9months
comparedwith one dose ofMV after 9months of age reducedmortality by 59% (25–81%). BCG-revaccination sig-
niﬁcantly enhanced BCG's effect against overall childmortality in two RCTs. In a natural experiment study of OPV
campaigns over a 13-year-period in Guinea-Bissau, each additional dose of OPV was associated with a 13% (4–
21%) reduction in mortality rate. The beneﬁcial NSEs of smallpox vaccination for survival increased signiﬁcantly
with the number of smallpox vaccination scars.
Interpretation: Revaccination with live vaccines led to substantial reductions in overall mortality. These ﬁndings
challenge current understanding of vaccines and may explain the beneﬁcial effects of campaigns with live
vaccines.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Revaccination1. Introduction
Live attenuated vaccines including measles vaccine (MV), BCG, oral
polio vaccine (OPV) and smallpox vaccine have beneﬁcial effects on sur-
vival beyond protection against the targeted infections (Aaby et al.,
1995; Kristensen et al., 2000; Aaby et al., 2010; Aaby et al., 2011;
Biering-Sørensen et al., 2012; Lund et al., 2015; Sørup et al., 2014).
Hence, these vaccines induce some form of nonspeciﬁc immunity. For
example, two doses of MV at 4.5 and 9 months reduced all-cause mor-
tality between 4.5 and 36 months by 30% (95% CI: 6–48%) compared
with a single dose at 9 months (Aaby et al., 2010). WHO recently
reviewed the evidence for nonspeciﬁc effects (NSEs) of BCG, MV and
diphtheria-tetanus-pertussis (DTP) vaccine and concluded that BCG
and MV were associated with beneﬁcial effects in the range of halving
mortality (Higgins et al., 2014; Strategic Advisory Group of Experts on
Immunization, 2014).depth Network, Apartado 861,
. This is an open access article underMeasles vaccination in presence of maternal antibodies is associated
with lower antibody responses. However, the beneﬁcial NSEs of early
MV were particularly strong if the initial MV was administered in the
presence of maternal measles antibody (Aaby et al., 2010; Benn et al.,
1997; Aaby et al., 2014). We speculated that NSEs are induced more
strongly with pre-existing immunity (Aaby et al., 2014). If this is the
case, then one would expect to see strong beneﬁcial NSEs of live atten-
uated vaccines when given to children who have speciﬁc immunity
froma previous vaccination or even in childrenwho already had the tar-
get disease.
We therefore reviewed available evidence to test the hypothesis that
revaccination with live vaccines is associated with additional strong
beneﬁcial NSEs. If conﬁrmed, it would contradict the disease-speciﬁc
understanding, as most live vaccines confer good speciﬁc protection
after a single dose, and very limited additional survival beneﬁt might
be expected after a second dose.
2. Methods
We searched PubMed andMedline for papers on revaccination with
BCG, MV, OPV and smallpox vaccine andmortality/death. The literaturethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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organised amajor review of the potential nonspeciﬁc effects of BCG vac-
cination and MV on child survival (Higgins et al., 2014; Strategic
Advisory Group of Experts on Immunization, 2014). Since this review
was also taken into consideration, it is unlikely that there would be ad-
ditional studies on BCG and MV that we have not found. It will be seen
(Supplementary Figs. 3–4) that therewere few studies on revaccination
with OPV or smallpox vaccine.
Papers in English, French, German, Spanish, Portuguese and Scandi-
navian languages were screened by two authors (CSB, PA) on the basis
of their abstract and potentially relevant papers were read. The studies
were classiﬁed as RCTs, natural experiments or observational studies
(Supplementary Figures). In the extraction of data, we compared the
age-adjusted mortality rate of individuals, who had received two vacci-
nations, with those who had received only one vaccination. The RCTs
had different designs as described in the result section. If several RCTs
had similar design, we combined their estimates with the meta-
command in Stata. For OPV and smallpox vaccination more than two
doses had been given and it was possible to estimate a linear trend for
additional doses of these vaccines.
Interventions may interact; thus to determine the effect of revacci-
nation with a live vaccine we tried to eliminate the effect of other inter-
ventions. For example, many studies have suggested that DTP has
negative effects on child survival when given after a live vaccine (Roth
et al., 2010; Aaby et al., in press; Benn and Aaby, 2012). We recently
reviewed the available data and found, in studies with registration of
vaccination status and prospective follow-up, that DTP given as the
most recent vaccination was associated with two-fold higher mortality
than not being DTP-vaccinated (Aaby et al., in press).We therefore cen-
sored children who were likely to receive DTP in the studies of revacci-
nation with BCG or MV. In one RCT (Aaby et al., 2010), many children
had previously received neonatal vitamin A supplementation (NVAS)
and NVAS neutralised the beneﬁcial effect of MV (Benn et al., 2014).
NVAS is unlikely to become ofﬁcial WHO policy as it has shown a nega-
tive effect on survival in African studies (Benn et al., 2015) and we have
restricted the analysis to those who did not receive NVAS. Restrictions
have been explained in footnotes to the tables.
Since naturalmeasles infection is easy to diagnose and is assumed to
provide life-long immunity, a child with known measles infection can
be seen as a childwhohas been “immunized” againstmeasles. Nonethe-
less such children have sometimes received a measles vaccine after-
wards. This provided an opportunity to test whether measles
vaccination of children who were known to have had natural measles
infection was associated with additional nonspeciﬁc beneﬁts (literature
search presented in Supplementary Fig. 5).Table 1
The mortality rate ratio (MRR) comparing two doses of MV with one dose of MV.
Country and period Age interval Comparison (vaccines)
RCTs of two doses of MV
Guinea-Bissau 1992–1994
(Benn et al., 1997)
9–18 months 2 MV vs 1 MV
Guinea-Bissau
2003–2009 (Aaby et al.,
2010)
9–18 months 2 MV vs 1 MV
Combined MRR
Natural experiment
Guinea-Bissau 1980–1982
(Aaby et al., 1993)
9–60 months 2 MV vs 1 MV
General MV campaign
Guinea-Bissau, 2006–2007
(Fisker et al., 2015)
1–4 years, follow-up
for 12 months
Had received routine MV and
campaign MV vs only routine MV
a The study was restricted to children who had received DTP3 before 9 months. If all childre
b Study restricted to children who had not received NVAS. If all children were included in th
c Adjusted for age, maternal age, maternal education and stratiﬁed by village cluster.3. Results
3.1. Measles Vaccine
Wewere able to identify two RCTs, a quasi-experimental study, and
a natural experiment with relevant data (Supplementary Fig. 1).
In Guinea-Bissau, two RCTs compared two doses of MV (at 4–
6 months and 9 months of age) with the WHO-recommended single
dose of MV at 9 month (Aaby et al., 2010; Benn et al., 1997). In both
RCTs randomisation took place at the initial enrolment at 4–6 months
of age. This design allowed us to compare mortality for two versus
one dose of MV after 9 months of age when the children had received
standard MV. The children were followed to 18 months of age since
booster doses of DTP at 18 months were common during the conduct
of both RCTs. In a combined analysis, two doses of MV were associated
with a 63% (22‐83%) mortality reduction between 9 and 18 months of
age (Table 1).
In the early 1980s, MV was administered in campaigns in Guinea-
Bissau once or twice a year; children who received their ﬁrst MV before
9 months received a second MV at the next visit (Aaby et al., 1993).
Hence, receiving one or two doses of MV was a natural experiment de-
termined by age at the time of the ﬁrst campaign. We adjusted for re-
gion, sex, measles infection and season at risk in the analysis.
Comparing the mortality of children from the time they received either
a second or a ﬁrst MV after 9months of age, thosewho received the sec-
ond dose had 59% (25–81%) lower mortality between 9 and 59 months
of age (Table 1) (Aaby et al., 1993).
After a MV campaign in rural Guinea-Bissau, we followed children
aged 1–4 years from the ﬁrst visit after the MV campaign in which
their vaccination status was determined, to 12 months after the cam-
paign, and compared their survival with children who had their vacci-
nation card examined in the similar period in the two previous years.
The children who had received both routine MV and campaign MV
had 50% (12–72%) lower mortality than the children who received
only routine MV in the previous two years.3.2. Additional Analyses: Measles Vaccination After Natural Measles
Infection
If revaccination in the presence of pre-existing vaccine-induced an-
tibodies enhances the nonspeciﬁc effects, one might surmise that mea-
sles vaccination of children with a history of measles infection could
have beneﬁcial effects. A search for such studies provided two relevant
studies (Supplementary Fig. 5).Administration of DTP Deaths/person-years
(pyrs) [N]
MRR two MV
vs one MV
DTP not given with MV; only children
with DTP3 before 9-months
0/72.1 pyrs [113] vs
2/70.3 pyrs [107]
0 (0–3.95)a
DTP not given with MV; all had DTP3
one month before enrolment
8/713.9 pyrs [1014] vs
39/1370.5 pyrs [1946]
0.39
(0.18–0.83)b
0.37
(0.17–0.78)
DTP not given in Guinea-Bissau in this
period
Not reported in paper 0.41
(0.19–0.75)
Effect analysed for those who had
received DTP3 before follow-up
16/1372 pyrs [2067] vs
60/2445 pyrs [3074]
0.50
(0.28–0.88)c
n were included the MRR was 0.33 (0.03–3.14).
e analysis the MRR was 0.61 (0.37–1.01).
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Bangladesh, 8134 measles-immunized children were matched by age
to 8134 unimmunized children from the control areas (Aaby et al.,
2003). In 136 matched pairs both children had had measles infection
previously. Among these pairs six unimmunized children died and
none of the immunized (p b 0.05). In an unpaired, adjusted analysis
13 of 924 children, who had measles and were given MV later, died;
27 of 891 children, who had measles but did not subsequently get MV,
died. Thus, among children who had measles, those who were later
given MV had a 55% (10–77%) reduction in overall mortality compared
with children who were not given MV (Aaby et al., 2003).
In a study of antibody responses toMV among 6–13months old Hai-
tian children (Holt et al., 1990), participating children were tested be-
fore vaccination for measles antibodies; 71 had pre-vaccination levels
which indicated prior infection according to the authors. During
2½ years of follow-up none of the 71 vaccinated children with pre-
vaccination antibodies died, whereas mortality was 7% (70/1056) for
the community controls (children in the same birth cohort who had
not received MV), resulting in a RR of 0 (0–0.77)). The study is compat-
ible with MV also having a beneﬁcial effect among previously infected
children, though it did not have a control group of children who had
measles antibodies from previous infection and were not measles
vaccinated.
3.3. BCG
Two studies of BCG revaccination contained information on child
survival (Roth et al., 2010; Sergent et al., 1954) (Supplementary Fig. 2).
A large trial was conducted in Alger 1935–1947 includingmore than
40,000 children whowere allocated to BCG or nothing at birth based on
the civil registration system (Sergent et al., 1954) (Table 2). Three oral
doses of BCG were provided with intervals of 2 days shortly after
birth; the children were revaccinated at 1, 3, 7 and 11 years of age.
The study provided no information on speciﬁc protection against tuber-
culosis (TB) or theproportion of deaths due to TB. The reduction in over-
all mortality was only 3% (−2 to 7%) in infancy (Table 2). The initial
doses provided at home by community nurses were often delayed.
The mortality analysis was intention-to-treat and deaths which oc-
curred before the children could have been BCG-vaccinated were in-
cluded in the analysis. After the ﬁrst revaccination, overall child
mortalitywas reduced by 17% (11–22%) in the BCG group. After the sec-
ond revaccination at 3 years, the reduction in mortality was 47% (38-
55%) between 3 and 4 years of age, a signiﬁcant increase in effect
(interaction tests, p b 0.001). The change from 17% to 47% is particularly
striking because the estimates are based on a per-protocol analysis of
those who did and did not get BCG. Since the initial random allocation
remained the same and the number of follow-up visits by study nurses
was the same for the BCG-vaccinated and BCG-unvaccinated children,
and since TB is unlikely to have caused many deaths in this young age
group, the results indicate that BCG revaccination may have conferred
strong additional beneﬁcial NSEs.
More recently we conducted a BCG revaccination trial in Guinea-
Bissau. In Bissau nearly all children receive BCG very early in life. Chil-
drenwere randomised to BCG revaccination (intra-dermally) or no vac-
cination at 19 months of age (Roth et al., 2010). When children had
received DTP booster before enrolment and therefore did not getTable 2
Trial with alternate allocation to BCG or no BCG at birth, at 1 year and at 3 years of age. Alger,
Age Mortality risk (deaths/p
Randomised to BCG-va
1st year of life (before and after enrolment) 20.4% (4121/20167)
2nd-3rd year (after ﬁrst revaccination of BCG group) 5.9% (1721/29310)
4th–5th year (after second revaccination of BCG group) 1.0% (243/25444)
a The paper indicated the number of children under observation at the beginning of each yebooster DTP after enrolment, BCG revaccination versus no BCG revacci-
nation at 19months of agewas associatedwith a 64% (1–87%) reduction
in mortality between 19 months and 60 months of age.
3.4. Oral Polio Vaccine (OPV)
OPV is recommended at birth and an additional three doses with
DTP vaccine at 6, 10 and 14 weeks of age. Hence, OPV revaccination is
normally givenwith DTP. Since DTPmay be associatedwith negative ef-
fects on mortality (Aaby et al., in press), it becomes difﬁcult to evaluate
whether revaccination with routine OPV has an independent beneﬁcial
effect.
One community study of OPV campaigns permitted us to evaluate
the effect of revaccination with OPV-only (Supplementary Fig. 3).
From 2002 to 2014we examined how national OPV campaigns in Guin-
ea-Bissau affected the mortality rate within seven RCTs (unpublished
data, authors). OPV campaigns – but not other campaigns - reduced
the mortality rate signiﬁcantly when controlled for age, season and
time trends. Since the children were to receive campaign-OPV several
times we assessed the effect of repeated doses assuming that all chil-
dren received all doses of campaign-OPV; each additional dose of OPV
was associated with an additional 13% (4–21%) reduction in mortality.
We also examined whether OPV revaccination in Denmark reduced
hospital admissions. In Denmark, in addition to three doses of
inactivated polio vaccine (IPV) in infancy, three doses of OPV (OPV1–
3) were administered without other simultaneous vaccinations at 2, 3
and 4 years of age until 2001. Children who had previously received
DTP-containing vaccines followed by OPV-1 around 2 years of age had
reduced hospital admission rate during the third year of life compared
with childrenwhohadDTP-containing vaccine as theirmost recent vac-
cination. There were further signiﬁcant reductions in admissions when
the children received OPV-2 andOPV-3 at 3 and 4 years of age (Sørup et
al., 2015).
3.5. Smallpox Vaccine
Two cohort studies from urban and rural areas of Guinea-Bissau
have examined the correlation between the number of smallpox vacci-
nation scars and subsequent mortality (Aaby et al., 2006; Jensen et al.,
2006) (Supplementary Fig. 4). As seen in Table 3, having a smallpox vac-
cination scarwas associatedwith signiﬁcantly lowermortality. This sur-
vival beneﬁt occurred 20–25 years after smallpox was eradicated and
vaccinations were stopped. In the urban study, there was a signiﬁcant
trend for larger reduction inmortality with increasing number of small-
pox vaccination scars (Aaby et al., 2006). Though not statistically signif-
icant, the trend was similar in the smaller rural study (Jensen et al.,
2006).
4. Discussion
4.1. Main Observations
RevaccinationwithMV, BCG, OPV and smallpoxwas associatedwith
strong reductions in overall mortality compared with having received
one dose only. The effect is not explained by speciﬁc disease-protection:
The vaccine efﬁcacy of MV is so high that very few childrenwould die of1935–1952 (Sergent et al., 1954).
erson-years)a Mortality rate ratio
(BCG/no BCG)
ccination Randomised to no BCG vaccination
21.0% (4008/19092) 0.97 (0.93–1.02)
7.1% (1919/27233) 0.83 (0.78–0.89)
1.8% (414/23034) 0.53 (0.45–0.62)
ar. It has been assumed that all were followed for 365 days.
Table 3
Number of smallpox vaccination scars and subsequent mortality.
Study (reference) Comparison
(deaths/persons)
Adjusted mortality rate
ratio (MRR, 95% CI)
MRR (95% CI) by
number of scars
Testing trend by number of scars
Bissau city (Aaby et al., 2006), Guinea-Bissau
(1998–2002), N = 1893 aged 25+ years
Vaccinia scar (75/1187)
vs no scar (60/500)
0.60 (0.41–0.87)
F: 0.51 (0.30–0.84)
M: 0.72 (0.42–1.24)
1 scar: 0.65
(0.40–0.91)
2 scars: 0.54
(0.29–0.97)
3+ scars: 0.44
(0.13–1.46)
Trend for decreasing MRR with number of
scars: MRR = 0.73 (95% 0.56–0.95)
Rural area (Jensen et al., 2006), Guinea-Bissau
(2003–2006), N = 367
Vaccinia scar (29/251) vs
no scar (9/35)
0.22 (0.08–0.61)
F: 0.19 (0.06–0.57)
M:0.40 (0.04–3.74)
1 scar: 0.24
(0.09–0.68)
2+ scars: 0.14
(0.03–0.56)
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large to be explained by better prevention of TB. Guinea-Bissau has
had no polio infection for the last 15 years so the beneﬁcial effects of
OPV revaccination are clearly nonspeciﬁc. Likewise, the reducedmortal-
ity after repeated smallpox vaccination is entirely nonspeciﬁc since
smallpox has been eradicated. The observation that revaccination is as-
sociatedwith strongmortality reductions challenges the current under-
standing of vaccines as mediators of speciﬁc protection only.
4.2. Strength and Weaknesses
The literature is sparse and most studies stem from our group. Al-
most all studies, however, were conducted prior to the formulation of
our hypothesis, and it is noteworthy that we were able to re-visit
existing studies and consistently ﬁnd support; there was no data
which contradicted the hypothesis. The data for MV, BCG and OPV
was mainly from RCTs or natural experiments so it seems unlikely
that selection bias and inherent differences between those who re-
ceived two doses or one dose can explain differences inmortality reduc-
tion. Since the children were randomised at the time of the ﬁrst
vaccination, they may no longer have been perfectly balanced at the
time of the second vaccination from which we compared the effect of
having received two doses of MV vaccine versus only one dose. Since
the intention-to-treat and the per-protocol analyses gave similar results
(Aaby et al., 2010) it is unlikely that such imbalances have had a major
impact on the estimates.
The studies of smallpox vaccinations were not randomised. In Guin-
ea-Bissau, smallpox vaccines were provided in campaigns, and it seems
unlikely that the potential determinants for being present at several
vaccinia campaigns in childhood could explain the observed large dif-
ferences in mortality risk. A smallpox scar is only a marker of smallpox
vaccination but smallpox vaccinewas a very effective vaccine, with long
lasting immunity which caused a characteristic scar in almost all vacci-
nated individuals; we have previously found good correlation between
records of smallpox vaccination and presence of a detectable scar (Aaby
et al., 2006). Though it is surprising that smallpox vaccination should
have an effect so many years after smallpox was eradicated, we have
found that it had strong beneﬁcial NSEs also in Denmark (Reickmann
et al., 2016). (TheDanish data only had information on the primary vac-
cination before school entry and is therefore not included in the present
analysis of revaccinations).
4.3. Interpretation
WHO recently reviewed the evidence and recommended further re-
search into NSEs (Higgins et al., 2014; Strategic Advisory Group of
Experts on Immunization, 2014). Emerging immunological studies
have shown that beneﬁcial NSEs of vaccines can be due both to T-cell
cross-reactions and training of the innate immune system
(Kleinnijenhuis et al., 2012; Bennet al., 2013). For example, BCG induces
epigenetic modulations that reprogram monocytes to a strongerresponse to unrelated antigens (Kleinnijenhuis et al., 2012). In hospital
studies from both Guinea-Bissau and Denmark, MV and OPV have pro-
vided the strongest nonspeciﬁc protection against lower respiratory in-
fections (Sørup et al., 2014; Sørup et al., 2015; Veirum et al., 2005;
Martins et al., 2014).
Revaccination has mainly been studied in relation to whether it
boosts the antibody response. The idea of examining NSEs after revacci-
nation with live vaccines came from several observations: First, we had
seen that giving early MV versus later MV was associated with reduced
overall mortality (Aaby et al., 2015). Second, we observed that the ben-
eﬁcial effect of an earlymeasles immunizationwas strongest in children
whohadmaternal antibodies at the time of ﬁrst vaccination (Aaby et al.,
2014). The latter ﬁnding led us to speculate that the formation of anti-
body-antigen complexes led to a particularly beneﬁcial immune re-
sponse (Aaby et al., 2014). The natural deduction was then that
vaccination in the presence of the child's own vaccine-induced or ill-
ness-induced antibody would be beneﬁcial.
We were able to verify that revaccination led to a strong beneﬁcial
nonspeciﬁc effect on overall survival, even though revaccinations
should have a very limited impact on overall mortality. These initial ob-
servations, derived deductions and veriﬁcations, add up to one unifying
hypothesis: vaccination with a live vaccine in the presence of pre-
existing immunity enhances the beneﬁcial NSEs of the live vaccine.
This hypothesis is supported by data from four different live vaccines
and has thereby produced a previously unrecognized pattern which
has the potential to explain contradictions, resolve enigmas and raise
questions which were never asked before (Kuhn, 1962).
For example, the literature regarding the decline towards theMillen-
nium Development Goal 4 (MDG4) to reduce child mortality with 2/3
between 1990 and 2015, does not consider an effect of general vaccina-
tion campaigns, but ascribes the decline to improvement in health ser-
vices (Amouzou et al., 2012). After a civil war, numerous military
coups, political instability and donor fatigue there is nothing to suggest
that health services have improved dramatically in Guinea-Bissau in the
2000s. Nonetheless the country experienced a large decline inmortality
in the 2000s and actually reached theMDG4. The repeated national OPV
andMV campaigns conducted since 1999may have hadmajor effects in
terms of reducing general mortality (Fisker et al., 2015; unpublished
data; authors).
The dramatic beneﬁcial effect of revaccination with live vaccines
should be seen in the context that some non-live vaccines, including
DTP, may be associated with increased mortality, particularly for girls
(Aaby et al., in press; Benn andAaby, 2012). Hence, a better understand-
ing and control of both beneﬁcial and deleterious NSEs could lead to
major improvements in health.4.4. Immunological Mechanisms
The most likely explanation for the observed beneﬁcial NSEs of re-
vaccination with live vaccines is that the immunising antigen forms
complexes with pre-existing antibody and these determine a
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tion against a range of infectious diseases. Infants given early MV in
the presence of maternal antibody had a marked survival advantage
that only became apparent after a booster dose of MV was given at
9 months of age (Aaby et al., 2014). Animal studies have shown that a
previous viral infectionmay lower viral replication of a subsequent het-
erologous viral infections due to stimulation of T-cell cross reactivity
(Selin et al., 2006).We suggest such T-cell reactivity is stimulated by an-
tigen-antibody complexes following a booster dose of MV or OPV,
which subsequently attenuates or protects against a range of viral infec-
tions. A human study has shown that BCG vaccination induces strong
antibody responses and these were further enhanced after a revaccina-
tionwith BCG 6months later (De Valière et al., 2005). Pre-existing anti-
bodies enhanced the internalization of BCG by neutrophils and
monocytes (De Valière et al., 2005). In mice, pre-opsonization of BCG
with anti-BCG-IgG potentiated phagocytosis by macrophages and led
to increased NO production (Silva et al., 2013). Intriguingly, BCG has
been shown to induce NOD2-dependent epigenetic modiﬁcations of
monocyteswhich lead to increased innate immune responses, so-called
“trained innate immunity” (Kleinnijenhuis et al., 2012). This effect,
though still partially present after a year (Kleinnijenhuis et al., 2014),
may wane over time. Thus, the beneﬁcial effect of BCG revaccination
may represent increased internalization of BCG into monocytes, in-
creased NOD2 activation and NO production, mediating even stronger
epigenetic effects leading to increased trained innate immunity. Inter-
estingly the effects of BCG immunotherapy against bladder cancer are
stronger andmore beneﬁcial in patients whohad received BCG vaccina-
tion prior to treatment initiation (Biot et al., 2012).
The exact immunological mechanisms underlying this phenomenon
obviously need to be explored. However, the consistency of the epide-
miological ﬁndings indicates that such mechanisms do exist. We need
to identify them.
4.5. Implications
The hypothesis that vaccination with a live vaccine in the presence
of existing immunity is associated with major beneﬁcial effects has
major implications for our understanding of vaccines and the way
theymaymodulate the immune system and induce NSEs.We have pro-
vided a few examples of immediate deductions and how theywere test-
ed. But there are many other deductions which need to be examined:
First, it may be beneﬁcial to provide live vaccines earlier whenmaternal
antibody is more likely to be present. For MV (Aaby et al., 2015), OPV
(Lund et al., 2015) and BCG (Storgaard et al., 2015) we have already
found that earlier vaccination confer stronger beneﬁcial NSEs. Second,
it might be beneﬁcial to vaccinate women of fertile age with live vac-
cines to increase the amount of maternal antibody they transfer. Third,
it might be beneﬁcial to give a live vaccine together with antibody
against the target disease. This could be tested by adding a small amount
of measles immunoglobulin to MV given at 9 months of age; the hy-
pothesis being that children who received immunoglobulin with MV
had improved health compared with children who received MV alone
(Aaby et al., 2010; Aaby et al., 2014). Fourth, it may be beneﬁcial to pro-
vide second doses of BCG and MV. Since GAVI is currently promoting a
secondmeasles-containing vaccine in the secondyear of life, this suppo-
sition could be tested in a RCT.
The hypothesis has major implications for immunization
programmes. If true it implies that much could be gained by
restructuring immunization schedules to beneﬁt from revaccinations.
Worryingly, several expected changes are likely to reduce the fre-
quency of revaccinations. With decreasing incidence of measles infec-
tion, the national measles vaccination campaigns, which have been
frequent since the 2000s, may be scaled down or stopped. Furthermore,
OPV campaigns will soon be stopped and OPV will be replaced with
inactivated polio vaccine (IPV). Both changes may result in increased
child mortality (Aaby et al., 2007), so it is urgent to test the potentialnonspeciﬁc beneﬁts of revaccination with these vaccines before they
are discontinued.
5. Conclusion
Revaccination with live vaccines enhances the beneﬁcial NSEs for
morbidity and mortality. This observation challenges the single-
disease-prevention paradigm underlying the current programmes by
showing much larger reductions in mortality than can be explained by
protection of those who did not respond after the ﬁrst vaccination.
The hypothesis has generated testable deductions which if veriﬁed
could lead to major changes in our understanding of vaccines and in
the organisation of vaccination programmes.
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